Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells

Dylan T. Jones(The Royal Melbourne Hospital), Stanley S. Stylli(The Royal Melbourne Hospital)
Molecular and Cellular Biochemistry
October 27, 2022
10.1007/s11010-022-04584-0
Cited by 7

Related Papers

Inhibition of Radiation and Temozolomide-Induced Invadopodia Activity in Glioma Cells Using FDA-Approved Drugs
|Translational Oncology|2018|26
Enhancement of invadopodia activity in glioma cells by sublethal doses of irradiation and temozolomide
|Journal of neurosurgery|2017|23
Inhibition of Radiation and Temozolomide-Induced Glioblastoma Invadopodia Activity Using Ion Channel Drugs
|Cancers|2020|15